Discovery of new ovarian cancer signaling hub points to target for limiting metastasis
Like pancreatic cancer, cancer of the ovaries is notorious for being discovered at a relatively late stage - after it has spread to other sites in the body. It is not called "the silent killer" for nothing. Fully two-thirds of women who are diagnosed find out at Stage 3 or later, once metastasis has begun. Fewer than 25% of such women survive 5 years - while the corresponding figure for those fortunate enough to be diagnosed at Stages 1 and 2, when the cancer is still localized, is between 70% and 90%.
FER activates a receptor called MET from below, i.e., in the absence of a growth factor like HGF docking at the receptor surface. MET is often overexpressed in aggressive ovarian cancers. Drs. Fan and Tonks call this form of activation "non-ligand-dependent," and in a complex series of biochemical and animal experiments, traced the pathway through which FER's binding to MET inside the cell sets off a cascade of cell-signaling events, all directly connected in prior research with cancer initiation. this suggests the potential utility of a drug blocking or inactivating FER.
Tonks Lab, CSHL/Genes&Development
Experiments in mice showed that FER helps to promote metastasis in ovarian cancer. Three mice with similar primary ovarian tumors are shown prior to surgery (top row) and following surgery (middle and bottom rows). A metastasis of the primary tumor appears in a lung of the mouse in the left column. FER was active in this mouse. The other two mice, in which FER has been inactivated genetically, remain cancer-free at the same time point following removal of the primary tumor.
Tonks Lab, CSHL/Genes&Development
A previously undiscovered pathway through which ovarian cells can be transformed into cancer cells. The key is a protein called FER, which can be found floating in the cell cytoplasm. CSHL scientists demonstrated that it is both overproduced in ovarian cancer cells, and, importantly, responsible for the elevated motility (ability to move) and invasiveness of such cells. This was observed in human ovarian cancer cells grown in culture and then in mouse models of the disease. Above, the team shows what happens when FER is rendered inactive in various kinds of ovarian cancer cells grown in culture. The left panel (A) shows motility; the right panel (B) invasiveness. FER is active in the control cells, top row, (A) and (B); FER is inactive in the corresponding cells in the bottom row, (A) and (B).
Tonks Lab, CSHL/Genes&Development
A team of researchers at Cold Spring Harbor Laboratory reports that they have arrived at "new insights into signaling events that underlie metastasis in ovarian cancer cells," says Gaofeng Fan, Ph.D., postdoctoral investigator who conducted most of the experiments, in the laboratory of his mentor, CSHL Professor Nicholas K. Tonks.
"The statistics point to the urgent need to address advanced disease - metastasis - in ovarian cancer," Fan says. "The problem is especially difficult because of a feature specific to this form of cancer: ovarian cells move around readily within the peritoneal cavity, via the peritoneal fluid, both under normal conditions, and also, unfortunately, when cancer is present. Thus, in addition to being able to colonize other sites in the body via blood vessels, ovarian cancer cells have another way of migrating. It's very hard to render patients free of the disease via surgery due to this diffusion feature."
Fan, Tonks and colleagues have found a previously undiscovered pathway through which ovarian cells can be transformed into cancer cells, one they think provides an excellent opportunity for targeting by new drugs, which, when combined with others now in development, may be able to stave off metastatic disease.
The newly uncovered pathway depends on activity of a protein called FER, a member of a family of proteins (called non-receptor tyrosine kinases) that add phosphate groups to other proteins. FER can be found floating in the cytoplasm of cells, and in a series of initial experiments, Fan and the team demonstrated that it is both "upregulated," i.e., overproduced, in ovarian cancer cells, and, importantly, responsible for the elevated motility and invasiveness of such cells. This was observed in human ovarian cancer cells grown in culture, and then in mouse models of the disease.
The key discovery made by the CSHL team is that FER is able to activate a receptor on the surface of ovarian cells "from below," as it were - by interacting with a portion of the receptor that penetrates the cell membrane and plunges into the cytoplasm. That receptor is a well known target in ovarian cancer. Called MET, it is typically activated when a growth factor called HGF binds it at the cell surface. MET is overexpressed in up to 60% of ovarian tumors and its activation has been implicated in both cancer initiation and in advanced cancers with poor prognosis.
Unsurprisingly, then, MET is the target of a number of drug development efforts, which have in common the aim of blocking MET's activation. So far, candidate MET inhibitors have had weak anti-tumor effects, when administered alone. "It seems ovarian cancer cells are finding other ways to activate pro-cancer signaling 'downstream' of MET," Fan says.
The significance of Fan and Tonks' research on FER is their discovery of how FER activates MET from below, i.e., in the absence of a growth factor docking at the receptor surface. They call this form of activation "non-ligand-dependent," and in a complex series of biochemical and animal experiments, traced the pathway through which FER's binding to MET inside the cell sets off a cascade of cell-signaling events, all directly connected in prior research with cancer initiation, including RAC1/PAK1 and SHP2-ERK.
By setting off these oncogenic cascades, FER, simply by adding a phosphate to the MET receptor, itself becomes a potentially attractive drug target. This is especially so since in animal models of ovarian cancer, Fan and the team demonstrated that FER's suppression reduced cancer cell motility and sharply reduced metastasis.
"We showed FER was essential for ovarian cancer cell motility and invasiveness, both in vitro and in vivo," Tonks says. "Considering that frequent amplification of MET accounts for resistance to therapies now in development and to poor prognosis, not only in ovarian cancer but in other cancers too, our findings pinpoint an important new signaling hub, involving the role of FER in MET activation. This may provide a novel strategy for therapeutic intervention, perhaps a drug to suppress FER being administered along with a MET inhibitor."
Original publication
Gaofeng Fan, Siwei Zhang, Yan Gao, Peter A. Greer, and Nicholas K. Tonks; "HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer"; Genes & Development; 2016
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
